Scynexis Inc (SCYX) Stock Price, Quote & News

Company Profile

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to t...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 201 884 5485

Website: www.scynexis.com

Address:

1 Evertrust Plaza, 13th Floor, Jersey City, United States

ImadogImaMut Feb. 3 at 6:15 PM

$SCYX compliance will come , then blow 52 wk high with GSK to finalize with the FDA the relaunch announcement could come any day. Then they roll this out US and other places . That is a ton of addressable mkt right there. Moderate to severe VVC in new or recurrent is a lot of potential Maybe GSK can do it cheaper and manufacture right in its facility in the US 🫡🤔🤗 Regardless of outcome, GSK looks petty and has not been favourable to scyx investors or women with VVC

0 · Reply

ImadogImaMut Feb. 3 at 1:00 PM

$SCYX that’s must be someone worried to sell 1 share at .72 👏It’s a good sign 😊

1 · Reply

whob007 Feb. 2 at 9:26 PM

$SCYX SEC filing, not sure if CEO bought 391K shares or was awarded, I think it is stock award/options?

2 · Reply

SnapCrackleStop Feb. 2 at 7:55 PM

$SCYX Quiite bullish at this point. $$$

0 · Reply

LemuelPitkin Feb. 2 at 4:47 PM

$SCYX “We are pleased to announce this important milestone for SCYNEXIS. With the transfer of the BREXAFEMME NDA now complete, GSK will be able to initiate regulatory interactions with the U.S. Food and Drug Administration (FDA) to discuss the relaunch of BREXAFEMME for vulvovaginal candidiasis (VVC) and refractory vulvovaginal candidiasis (rVVC) in the U.S. market,” said David Angulo, M.D., President and Chief Executive Officer. “Furthermore, SCYNEXIS stands to receive net sales milestones and royalties following the relaunch providing a significant future source of non-dilutive capital.” https://ir.scynexis.com/news-events/press-releases/detail/354/scynexis-completes-transfer-of-brexafemme-new-drug#:~:text=With%20the%20transfer%20of%20the,the%20U.S.%20Food%20and%20Drug

0 · Reply

LemuelPitkin Feb. 2 at 4:32 PM

$SCYX Reminder: Based on the April 2022 public offering, SCYNEXIS (SCYX) issued warrants to purchase up to an aggregate of 15,000,000 shares of common stock. Key details regarding these warrants: Strike Price: $3.45 per share. Expiration Date: Seven years from issuance (April 2022), making them due to expire in April 2029. Context: These warrants were issued alongside pre-funded warrants ($0.001 strike) and common stock in a $45 million offering that closed on April 26, 2022. Additional Terms: The warrants included a provision allowing holders to purchase a pre-funded warrant instead of common stock at the $3.45 exercise price.

3 · Reply

LemuelPitkin Feb. 2 at 4:10 PM

$SCYX Who here has access to Bloomberg Terminal? The "community" (don't get me started) here is going to need you over the coming few months. I think I remember Viktor/Winston sharing this information during the first rollout with Amplity Health during the Covid Plandemic/lockdowns. "Bloomberg Terminal tracks per-unit drug sales and prices primarily through Bloomberg Intelligence (BI) and specialized functions like BI PHRM RX , integrating 5+ years of data from First Databank and 7+ years from Symphony Health. It provides retail/institutional prescription volume, gross sales, and National Average Drug Acquisition Cost (NADAC) for U.S. markets. "

3 · Reply

ViktorSinclair Feb. 2 at 3:43 PM

$SCYX Asked AI about getting 247 to the market... after lots of caveats, the bottom line was this: If everything goes well with the upcoming clinical trials and the data are strong, SCY-247 could eventually be approved and marketed, most realistically in the second half of this decade (e.g., 2027–2030 timeframe). But it is not yet close to market — it’s still in early clinical stages

0 · Reply

showmethemoney75 Feb. 2 at 2:39 PM

$SCYX Should jump to 3.00 with some goods news on Ibrexafungerp

2 · Reply

btm811 Jan. 30 at 3:30 PM

$SCYX Its actually going to be hilarious when this compliance extension still doesn’t do anything and it still stays under a dollar

3 · Reply

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Nov 19, 2025, 7:00 AM EST - 2 months ago

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

Nov 5, 2025, 4:20 PM EST - 3 months ago

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 15, 2025, 8:00 AM EDT - 3 months ago

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

Sep 4, 2025, 8:30 AM EDT - 5 months ago

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

Aug 13, 2025, 4:30 PM EDT - 6 months ago

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

May 28, 2025, 8:30 AM EDT - 8 months ago

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

Mar 12, 2025, 5:08 PM EDT - 11 months ago

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

Nov 6, 2024, 4:30 PM EST - 1 year ago

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 10, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 3, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

Aug 27, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 23, 2024, 7:00 AM EDT - 1 year ago

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

May 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 30, 2024, 4:05 PM EDT - 1 year ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

Apr 9, 2024, 4:05 PM EDT - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Apr 2, 2024, 10:04 AM EDT - 2 years ago

Scynexis: Update Following Restructuring Of GSK Deal

Mar 28, 2024, 4:01 PM EDT - 2 years ago

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Jan 29, 2024, 5:15 PM EST - 2 years ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

Jan 8, 2024, 4:00 AM EST - 2 years ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Jan 5, 2024, 8:30 AM EST - 2 years ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

Jan 4, 2024, 7:00 AM EST - 2 years ago

JANUARY 8 FINAL DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 29, 2023, 4:00 AM EST - 2 years ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with to Contact the Firm

Dec 28, 2023, 9:00 AM EST - 2 years ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options

Dec 22, 2023, 7:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 21, 2023, 8:00 AM EST - 2 years ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Dec 19, 2023, 5:30 AM EST - 2 years ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 18, 2023, 6:46 PM EST - 2 years ago

Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'

Dec 18, 2023, 6:15 AM EST - 2 years ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 13, 2023, 7:00 AM EST - 2 years ago

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 8, 2023, 5:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMIDNER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 6, 2023, 7:00 AM EST - 2 years ago

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 4, 2023, 7:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 1, 2023, 6:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 30, 2023, 8:30 AM EST - 2 years ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options

Nov 29, 2023, 7:50 PM EST - 2 years ago

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 22, 2023, 11:45 PM EST - 2 years ago

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 21, 2023, 7:00 AM EST - 2 years ago

IMPORTANT JANUARY DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 19, 2023, 11:45 PM EST - 2 years ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 17, 2023, 11:15 AM EST - 2 years ago

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

ImadogImaMut Feb. 3 at 6:15 PM

0 · Reply

ImadogImaMut Feb. 3 at 1:00 PM

$SCYX that’s must be someone worried to sell 1 share at .72 👏It’s a good sign 😊

1 · Reply

whob007 Feb. 2 at 9:26 PM

$SCYX SEC filing, not sure if CEO bought 391K shares or was awarded, I think it is stock award/options?

2 · Reply

SnapCrackleStop Feb. 2 at 7:55 PM

$SCYX Quiite bullish at this point. $$$

0 · Reply

LemuelPitkin Feb. 2 at 4:47 PM

0 · Reply

LemuelPitkin Feb. 2 at 4:32 PM

3 · Reply

LemuelPitkin Feb. 2 at 4:10 PM

3 · Reply

ViktorSinclair Feb. 2 at 3:43 PM

0 · Reply

showmethemoney75 Feb. 2 at 2:39 PM

$SCYX Should jump to 3.00 with some goods news on Ibrexafungerp

2 · Reply

btm811 Jan. 30 at 3:30 PM

$SCYX Its actually going to be hilarious when this compliance extension still doesn’t do anything and it still stays under a dollar

3 · Reply

ImadogImaMut Jan. 30 at 3:09 PM

$SCYX ok so you know how this works . I just paid the offer side for 200 the ask was at .7299 I was filled at .7255 These to me are evidence of cheating? Was there a seller there at .7255? I can’t even put a bid in in 1/100 I can only buy or sell. 🤧🤔🙂‍↔️🙂‍↕️

1 · Reply

whob007 Jan. 29 at 6:42 PM

$SCYX Totally undervalued, the recent news is clear SCY-247 will be a blockbuster and meet a major need in hospitals

1 · Reply

jonhie Jan. 29 at 3:42 PM

$SCYX Next milestone depends on GSK

0 · Reply

ViktorSinclair Jan. 29 at 1:11 PM

$SCYX https://finance.yahoo.com/news/scynexis-announces-presentations-highlighting-potent-130000673.html Interesting, but we need corporate news, not more drug news. The stock rarely moves on drug news, but always moves on company related news. David, FOCUS ON THE COMPANY, not so much the drug. If you can't do that, step down and hire a real CEO focused on the company and shareholders then you can play in your drug sandbox. Because you have failed shareholders, you need to admit that and correct your wrongs.

1 · Reply

XZeroDelta Jan. 28 at 2:46 PM

$SCYX SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) Here is the link: https://ir.scynexis.com/news-events/press-releases/detail/357/scynexis-announces-presentations-highlighting-the-potent

1 · Reply

pjinvestmentco Jan. 28 at 1:46 PM

$SCYX not sure if David fully understands that the stock price is in the hands of the pump and dump traders and naked shorts.

0 · Reply

ImadogImaMut Jan. 28 at 12:49 PM

$SCYX All trades in the 70s are form t trades fake news for sure 👍 Morning y’all real homosapiens

0 · Reply

InkaTwits Jan. 27 at 7:51 PM

$SCYX I’m in 20k AvP 0.8041.

0 · Reply

ViktorSinclair Jan. 27 at 11:21 AM

$SCYX we have to get out from underneath of all the warrants they issued. i warned them about this multiple times. they destroyed the stock price and kept it pinned below 3 from the moment it was announced. yes it created an incentive to buy the new issues but no one wants to make a big investment knowing they will be automatically diluted if the price goes moves. they never really understood that. i dont see a way out until they expire in 2029 and some are indefinite i think.

2 · Reply

StockScanners Jan. 27 at 3:30 AM

$SCYX reached .86

0 · Reply

ViktorSinclair Jan. 26 at 8:42 PM

$SCYX

0 · Reply

ImadogImaMut Jan. 26 at 10:19 AM

$SCYX Blew thru that 200 MDA - Got some more shovelling to do tho ❄️🥶😳

0 · Reply

Market Cap	29.84M
Revenue (ttm)	3.75M
Net Income (ttm)	-21.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	0.72
Profit Margin	-567.73%
Debt to Equity Ratio	0.00

Volume	437,500
Avg Vol	494,308
Day's Range	N/A - N/A
Shares Out	41.97M
Stochastic %K	48%
Beta	1.34
Analysts	Strong Sell
Price Target	$3.67